Department of Pharmacology, School of Basic Medicine, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China.
Department of Pharmacology, School of Basic Medicine, Guizhou University of Traditional Chinese Medicine, Guiyang, 550025, Guizhou, China.
Nat Commun. 2024 Apr 11;15(1):3129. doi: 10.1038/s41467-024-47493-0.
The essence of difference between hemostasis and thrombosis is that the clotting reaction is a highly fine-tuned process. Vascular protein disulfide isomerase (PDI) represents a critical mechanism regulating the functions of hemostatic proteins. Herein we show that histidine-rich glycoprotein (HRG) is a substrate of PDI. Reduction of HRG by PDI enhances the procoagulant and anticoagulant activities of HRG by neutralization of endothelial heparan sulfate (HS) and inhibition of factor XII (FXIIa) activity, respectively. Murine HRG deficiency (Hrg) leads to delayed onset but enhanced formation of thrombus compared to WT. However, in the combined FXII deficiency (F12) and HRG deficiency (by siRNA or Hrg), there is further thrombosis reduction compared to F12 alone, confirming HRG's procoagulant activity independent of FXIIa. Mutation of target disulfides of PDI leads to a gain-of-function mutant of HRG that promotes its activities during coagulation. Thus, PDI-HRG pathway fine-tunes thrombosis by promoting its rapid initiation via neutralization of HS and preventing excessive propagation via inhibition of FXIIa.
止血和血栓形成的本质区别在于凝血反应是一个高度精细的过程。血管蛋白二硫键异构酶(PDI)代表了调节止血蛋白功能的关键机制。本文表明,富含组氨酸糖蛋白(HRG)是 PDI 的底物。PDI 还原 HRG 通过中和内皮肝素硫酸(HS)和抑制因子 XII(FXIIa)活性,分别增强 HRG 的促凝和抗凝活性。与 WT 相比,小鼠 HRG 缺乏(Hrg)导致血栓形成的潜伏期延长但程度增强。然而,在 FXII 缺乏(F12)和 HRG 缺乏(通过 siRNA 或 Hrg)的组合中,与单独的 F12 相比,血栓形成进一步减少,证实了 HRG 的促凝活性独立于 FXIIa。PDI 的靶二硫键突变导致 HRG 的获得性功能突变,在凝血过程中促进其活性。因此,PDI-HRG 途径通过中和 HS 促进其快速启动,并通过抑制 FXIIa 防止过度传播来精细调节血栓形成。